Eltivutabart clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses eltivutabart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Trishula Therapeutics, Inc. (3)
Often tested with
Tested in the same studies.
Budigalimab (2) · Modified FOLFOX6 Regimen (1)
Studies
Open first, then newest update. How each study uses eltivutabart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC PatientsCompletedPhase 2Trishula Therapeutics, Inc.NCT06119217Written as TTX-030, nab-paclitaxel and gemcitabineHow we know
- TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced CancersCompletedPhase 1Trishula Therapeutics, Inc.NCT04306900Written as TTX-030, budigalimab and mFOLFOX6How we know
- TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced CancersCompletedPhase 1Trishula Therapeutics, Inc.NCT03884556Written as TTX-030How we know
Codes
What other systems call eltivutabart · ClinicalTrials.gg INT016205
- UNII (FDA) CA5TVG8F7PELTIVUTABARTOne source FDA
- NCI Thesaurus C162693EltivutabartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | CA5TVG8F7P | ELTIVUTABART | One source FDA |
| NCI Thesaurus | C162693 | Eltivutabart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.